Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that
exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its …

Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an
invaluable drug target for the pharmacological management of pituitary adenomas and …

Somatostatin (SST), a regulatory peptide, is produced by neuroendocrine, inflammatory, and
immune cells in response to ions, nutrients, neuropeptides, neurotransmitters, thyroid and …

Although opioids are highly effective for the treatment of pain, they are also known to be
intensely addictive. There has been a massive research investment in the development of …

In 1972, Brazeau et al. isolated somatostatin (somatotropin release-inhibiting factor, SRIF), a
cyclic polypeptide with two biologically active isoforms (SRIF-14 and SRIF-28). This event …

Somatostatin analogs (SA) are widely used in acromegaly, either as first-line or adjuvant
treatment after surgery. First-line treatment with these drugs is generally used in the patients …

G protein-coupled receptors (GPCRs) can stimulate the mitogen-activated protein kinase
(MAPK) cascade and thereby induce cellular proliferation like receptor tyrosine kinases …

This review summarizes the latest advances that have been made to elucidate the
somatostatinergic system in respect to somatostatin receptor evolution, the development of …

Somatostatin limits cell growth by inhibiting the proliferative activity of growth factor
receptors. In this study, it is shown that in pituitary tumor cells, the somatostatin analogue …

Acromegaly is a chronic disease with increased morbidity and mortality, where usually
multiple treatment modalities are used. The somatostatin analogs (SSAs) are the mainstay of …